The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Allied Universal, a leading facility services company and the largest security force in North America, together with John Jay College and the Metropolitan Healthcare Security Directors Association (MHSDA), will host a “Plan to Live” seminar to educate healthcare providers on best practices to handle an active shooter situation and other threats. The free seminar will be held Tues., May 16, from 9 a.m. to 1:30 p.m. in the college’s Moot Court at 899 10th Avenue, New York City.
“Active shooters are not the only risks that healthcare facilities face,” said Kevin Francis, Business Development Specialist, Allied Universal. “Healthcare facilities may encounter aggressive assailants, bomb threats, and terrorist attacks. Our seminar provides tips and information from leading experts to help them prepare for, survive and recover from an attack.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7883351-allied-universal-john-jay-active-shooter-seminar/
